Compare Immunovant Inc. Common Stock (IMVT) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Nutanix Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Nutanix Inc trades at $72.61 (market cap $19.78B). The key difference: Nutanix Inc is far larger — about 3.2× Immunovant Inc. Common Stock's market cap, and Nutanix Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Nutanix Inc for 17 Days on average.
| IMVT | NTNX | |
|---|---|---|
Market Cap | $6.25B | $19.78B |
Volume | 1,755,411 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $44.96 | $73.42 |
52-Week Low | $17.03 | $34.41 |
Typical Hold Time | 0 Days | 17 Days |
Enterprise Value | $5.35B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nutanix (NTNX) trades at $73.42, showing minimal daily movement with a 0.01% gain. The stock maintains a bullish technical outlook with strong moving average signals, though oscillators suggest some near-term caution. Fundamentally, the company demonstrates robust profitability with an 86.8% gross margin and has consistently beaten earnings expectations in recent quarters. Recent Gartner Magic Quadrant recognitions highlight competitive strength in server virtualization and hybrid infrastructure.
The investment outlook remains positive with 62.5% analyst buy ratings and a $76.11 consensus price target offering 3.7% upside. Key opportunities include external storage growth and AI initiatives, while risks involve supply chain pressures and competitive market dynamics. Revenue growth acceleration to $2.9B in 2026 with 52.8% net margins supports the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
